Xocova FDA Approval Closes Omicron-Era Gap
Adults and adolescents aged 12 and older who are exposed to COVID-19 now have a new option: the FDA approved Xocova (ensitrelvir) on June 1 as the first and only oral medication in the United States cleared specifically to prevent COVID-19 after a known exposure. The drug is made by Osaka-based Shionogi, developed in collaboration with Hokkaido University, and cuts the risk of developing symptomatic COVID-19 by 67% in household contacts when started within 72 hours. That 67% risk reduction — measured in a Phase 3 trial of more than 2,000 SARS-CoV-2-negative household contacts — was confirmed regardless of vaccination status or prior infection, making it the first pharmaceutical tool in the U.S. designed to intercept the virus before symptoms begin.
For clinicians, the approval closes a gap that had been open since bamlanivimab/etesevimab, the only prior authorized COVID post-exposure option, was withdrawn from use when it proved ineffective against Omicron variants. No oral prophylaxis had existed since, leaving physicians in the position of advising isolation and watchful waiting after high-risk household exposures. That window now has a drug.
COVID-19 Still Kills Tens of Thousands Each Year
The approval arrives against a backdrop of continued COVID-19 mortality. Between October 1, 2025 and May 23, 2026, the CDC estimated 3.8 to 12.4 million new U.S. COVID-19 cases, generating between 120,000 and 240,000 hospitalizations and between 13,000 and 42,000 deaths. Source: Shionogi Announces FDA Approval of Xocova, citing CDC burden estimates Omicron and its subvariants continue to drive transmission, and studies suggest up to 47% of individuals sharing a home with a confirmed COVID case will develop COVID-19 themselves.
Dr. Frederick Hayden, Richardson Professor Emeritus of Clinical Virology at the University of Virginia School of Medicine and the lead author of the SCORPIO-PEP study published in the New England Journal of Medicine, described the post-exposure prophylaxis strategy as having potential benefit well beyond household contacts. Nursing homes, long-term care facilities, and travel-related exposures are all scenarios where early post-exposure intervention could limit spread, he noted. Infectious disease specialists on Xocova
How Xocova Differs from Paxlovid at the Molecular Level
Xocova works by blocking the SARS-CoV-2 main protease — known as Mpro or 3CL protease — the enzyme the virus depends on to cleave its polyprotein precursors into the non-structural proteins required for replication. Without a functioning Mpro, the virus cannot assemble new copies of itself inside a host cell. This places Xocova in the same pharmacological class as nirmatrelvir, the active ingredient in Pfizer's Paxlovid, which also targets Mpro.
The molecular distinction between the two drugs is significant. Nirmatrelvir works by forming a covalent bond with the Cys145 residue in Mpro's active site — it attaches chemically to the enzyme and locks it. Ensitrelvir, by contrast, is the first noncovalent, nonpeptide oral Mpro inhibitor: it targets the same S1, S2, and S1' subsites of Mpro through a hydrogen bonding network rather than a chemical bond. Molecular mechanism of ensitrelvir: Communications Biology, Lin et al. 2023 This structural difference has a practical consequence: because ensitrelvir does not require ritonavir as a pharmacokinetic booster, it avoids the extensive drug-drug interaction profile that makes Paxlovid difficult or contraindicated for patients on immunosuppressants, anticoagulants, and certain cardiac medications. Ensitrelvir demonstrated inhibitory concentrations against Mpro (IC50 approximately 0.049 micromolar) comparable to nirmatrelvir's 0.044 micromolar in independent structural analysis, and structural studies confirm it remains effective against all five recognized SARS-CoV-2 variants of concern because the variant-specific mutations in Mpro are located more than 20 angstroms from the drug's binding pocket.
The five-day treatment course consists of 375 mg on day one (three tablets taken as a single dose), followed by 125 mg daily on days two through five. Treatment must begin as soon as possible and the FDA prescribing information specifies it should start within 72 hours of contact with an infected individual. Xocova prescribing information
SCORPIO-PEP Trial: What the Data Show
The FDA's decision rests on SCORPIO-PEP, a global, double-blind, randomized, placebo-controlled Phase 3 study and the only trial of an oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 after a household exposure. The trial enrolled 2,387 participants aged 12 and older who were living with a symptomatic COVID-19 case and who tested negative for SARS-CoV-2 at baseline screening. Participants were randomized 1:1 to receive ensitrelvir or placebo; treatment was initiated within three days of when the household index patient's symptoms began.
In the primary endpoint analysis — 2,041 participants who were SARS-CoV-2 negative at baseline by central laboratory confirmation — only 2.9% of those in the ensitrelvir group developed symptomatic COVID-19 by day 10, compared with 9.0% in the placebo group. The relative risk ratio was 0.33, representing a 67% reduction in the probability of developing symptomatic disease. Hayden FG et al., NEJM 2026, doi:10.1056/NEJMoa2509306 A secondary analysis that included all participants regardless of baseline serostatus showed a 57% risk reduction.
More than 99% of household contacts tested positive for SARS-CoV-2 antibodies at baseline, meaning nearly the entire trial population had prior exposure through infection, vaccination, or both. The drug performed equally well in this highly immune population, confirming that Xocova's benefit does not depend on immunological naivety.
In terms of tolerability, adverse event rates were nearly identical between the treatment and placebo groups — 15.1% versus 15.5%, respectively. The most common adverse reactions were headache, diarrhea, and cough. No cases of dysgeusia (altered taste) were attributed to Xocova — a side effect that has created adherence challenges with competing antivirals.
Prescribing Cautions Clinicians Need to Know
Xocova's prescribing information carries several warnings practitioners must review before initiating treatment.
Embryofetal toxicity: Available data on use during pregnancy are insufficient to establish risk, and animal studies showed adverse developmental effects at exposures approximately nine times the recommended human dose. Pregnancy should be ruled out before initiating treatment, and the drug should not be used during pregnancy or breastfeeding; women should not breastfeed during treatment or for two weeks after the final dose. Xocova prescribing information
Drug interactions: Ensitrelvir is a substrate and strong inhibitor of CYP3A enzymes. It is contraindicated in patients taking drugs primarily metabolized by CYP3A for which elevated plasma concentrations could cause serious or life-threatening events, and in patients taking strong CYP3A inducers, which could reduce ensitrelvir concentrations and eliminate its antiviral effect. Unlike Paxlovid's ritonavir-boosted interaction profile, ensitrelvir's CYP3A interaction burden is different in character — but prescribers must still conduct a comprehensive medication review before initiating therapy, particularly for patients on calcineurin inhibitors, certain statins, antiarrhythmics, and ergot derivatives.
Xocova's U.S. History: Prevention Yes, Treatment No
Ensitrelvir has been available in Japan since November 2022, when it received emergency regulatory approval there for COVID-19 treatment, and received full Japanese approval in March 2024. The drug is also available in Singapore via a special access route, and regulatory review is ongoing at the European Medicines Agency for both post-exposure prophylaxis and treatment indications, as well as in Taiwan for the prophylaxis indication.
The U.S. development story, however, requires an important distinction. Shionogi's U.S. Phase 3 treatment trial — SCORPIO-HR — failed its primary endpoint in May 2024, missing a statistically significant reduction in the time to sustained resolution of 15 common COVID-19 symptoms. Shionogi's treatment trial failed primary endpoint As a result, Xocova in the United States is approved only for post-exposure prophylaxis — preventing COVID-19 before symptoms begin in people who have been exposed. It is not approved here for treatment of active COVID-19 infection. The drug that could not shorten illness after symptoms began in its global treatment trial succeeded in the distinct clinical question of the prevention window: whether the drug can stop infection from taking hold in the critical hours to days between exposure and symptom onset.
The FDA accepted Shionogi's New Drug Application in September 2025 under Priority Review, and approved the drug on June 1, 2026 — fifteen days ahead of the official PDUFA action deadline of June 16. FDA NDA acceptance September 2025
How Does Ensitrelvir Prevent COVID-19 Without Ritonavir?
Paxlovid remains available for the treatment of mild to moderate COVID-19 in high-risk adults after symptom onset — a fundamentally different indication from Xocova's post-exposure prophylaxis use. Paxlovid's active ingredient, nirmatrelvir, forms a covalent bond with Mpro and requires ritonavir as a pharmacokinetic booster to maintain adequate drug levels; that co-administration creates the extensive drug-interaction profile that limits Paxlovid's use in patients on many common medications. Xocova's noncovalent mechanism provides adequate oral bioavailability and tissue distribution without a booster drug, but it comes with its own CYP3A interaction concerns requiring careful prescriber review.
The two drugs are not interchangeable: Paxlovid is taken after a COVID-19 diagnosis; Xocova is taken after exposure but before symptoms appear. The timing window for Xocova is narrow — within 72 hours of contact — meaning patients and prescribers must act quickly.
Frequently Asked Questions
What is COVID-19 post-exposure prophylaxis, and who qualifies for Xocova?
Post-exposure prophylaxis for COVID-19 means taking a medication after a known exposure to an infected person — before symptoms develop — to reduce the likelihood of becoming ill. Xocova (ensitrelvir) is FDA-approved for adults and adolescents aged 12 and older who have had close contact with a confirmed COVID-19 case. It must be started as soon as possible, within 72 hours of that contact, and taken for five days.
How does Xocova differ from Paxlovid?
Paxlovid is taken after COVID-19 symptoms appear and is approved for treatment of active infection in high-risk adults. Xocova is taken after exposure but before symptoms, serving a prevention role. Mechanistically, Paxlovid's nirmatrelvir binds covalently to the viral Mpro enzyme and requires ritonavir as a booster, which creates significant drug interactions. Ensitrelvir binds noncovalently through a hydrogen bonding network and requires no ritonavir booster — though it still carries CYP3A drug interaction risks that prescribers must evaluate individually.
Is Xocova approved to treat COVID-19?
Not in the United States. Shionogi's Phase 3 treatment trial (SCORPIO-HR) failed its primary endpoint in 2024, and the FDA has approved Xocova only for post-exposure prophylaxis — preventing COVID-19 before symptoms begin in people who have been exposed. Xocova is approved for both treatment and prevention in Japan, but the U.S. indication is limited to the preventive use.
Will Xocova work if I am vaccinated or have had COVID before?
Yes. In the SCORPIO-PEP trial, over 99% of household contacts already had SARS-CoV-2 antibodies from prior vaccination or infection. The 67% risk reduction held across this entire immune population, confirming that Xocova's benefit does not depend on the patient being immunologically naive to the virus.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
